10:38 AM EST, 11/07/2024 (MT Newswires) -- PharmAla Biotech Holdings ( MDXXF ) was up more than 19% in morning trade Thursday after saying has been contracted as a supplier of MDMA to a clinical trial at Yale University.

"Requests for clinical trial material - LaNeo MDMA - for research purposes continues to occupy the company at this time," said Nicholas Kadysh, CEO.

PharmAla also said it has settled $100,000 in debt through the issue of shares. The deemed price per share will be determined at the time of settlement.

PharmAla was last seen up $0.02, to $0.2050, on the Canadian Securities Exchange.

Price: 0.20, Change: +0.02, Percent Change: +8.11